- Home
- ATAT vs DNLI Comparison
ATAT vs DNLI Comparison
Compare ATAT & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAT
- DNLI
- Stock Information
- Founded
- ATAT 2013
- DNLI 2013
- Country
- ATAT China
- DNLI United States
- Employees
- ATAT N/A
- DNLI N/A
- Industry
- ATAT Hotels/Resorts
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATAT Consumer Discretionary
- DNLI Health Care
- Exchange
- ATAT Nasdaq
- DNLI Nasdaq
- Market Cap
- ATAT 3.8B
- DNLI 3.1B
- IPO Year
- ATAT 2022
- DNLI 2017
- Fundamental
- Price
- ATAT $31.26
- DNLI $20.73
- Analyst Decision
- ATAT Strong Buy
- DNLI Strong Buy
- Analyst Count
- ATAT 2
- DNLI 13
- Target Price
- ATAT $23.69
- DNLI $37.91
- AVG Volume (30 Days)
- ATAT 1.2M
- DNLI 814.8K
- Earning Date
- ATAT 03-27-2025
- DNLI 03-04-2025
- Dividend Yield
- ATAT 1.44%
- DNLI N/A
- EPS Growth
- ATAT 162.91
- DNLI N/A
- EPS
- ATAT 1.20
- DNLI N/A
- Revenue
- ATAT $950,764,843.00
- DNLI N/A
- Revenue This Year
- ATAT $55.64
- DNLI N/A
- Revenue Next Year
- ATAT $25.38
- DNLI $289.18
- P/E Ratio
- ATAT $26.66
- DNLI N/A
- Revenue Growth
- ATAT 76.11
- DNLI 204.74
- 52 Week Low
- ATAT $15.22
- DNLI $14.56
- 52 Week High
- ATAT $33.32
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- ATAT 66.64
- DNLI 42.56
- Support Level
- ATAT $31.01
- DNLI $21.33
- Resistance Level
- ATAT $33.32
- DNLI $22.81
- Average True Range (ATR)
- ATAT 1.44
- DNLI 1.27
- MACD
- ATAT 0.41
- DNLI -0.10
- Stochastic Oscillator
- ATAT 72.94
- DNLI 15.83
About ATAT Atour Lifestyle Holdings Limited
Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.